SAN DIEGO, March 8, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD ), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Aethlon's request to export its Hemopurifier® medical device to India.
The FDA's approval was granted under Section 801 (e) of the Federal Food, Drug, and Cosmetic Act, as amended (the Act). Section 801 (e) of the Act covers class III medical devices, such as the Hemopurifier®, that have not yet received an approved Premarket Approval in the US by the FDA. Section 801 (e) applies to medical devices that are acceptable to the importing country and that are manufactured under the FDA's Good Manufacturing Practices.
"The granting of our export license by FDA represents a critical step in our strategy to initiate future commercialization of our Hemopurifier® in India," stated Jim Joyce, Aethlon Chairman and CEO.
Aethlon is currently conducting a clinical study entitled: "Use of the Aethlon Hemopurifier® in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy" at the Medicity Institute (Medicity) near Delhi, India. The Medicity is a $360 million multi-specialty medical institute recently established on a 43-acre campus to be a premier center of medical tourism in India. A clinical goal of the Aethlon-Medicity study will be to demonstrate that the Hemopurifier® is able to accelerate the benefit of HCV standard of care (SOC) drug regimens. Therapeutic filtration at the outset of SOC improves early virus reduction kinetics to levels associated with that of patients most likely t